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Phthalocyanine-Peptide Conjugates for Epidermal Growth
Factor Receptor Targeting1
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Abstract
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Four phthalocyanine (Pc)-peptide conjugates designed to target the epidermal growth factor
receptor (EGFR) were synthesized and evaluated in vitro using four cell lines: human carcinoma
A431 and HEp2, human colorectal HT-29, and kidney Vero (negative control) cells. Two peptide
ligands for EGFR were investigated: EGFR-L1 and -L2, bearing 6 and 13 amino acid residues,
respectively. The peptides and Pc-conjugates were shown to bind to EGFR using both theoretical
(Autodock) and experimental (SPR) investigations. The Pc-EGFR-L1 conjugates 5a and 5b
efficiently targeted EGFR and were internalized, in part due to their cationic charge, whereas the
uncharged Pc-EGFR-L2 conjugates 4b and 6a poorly targeted EGFR maybe due to their low
aqueous solubility. All conjugates were non-toxic (IC50 > 100 µM) to HT-29 cells, both in the
dark and upon light activation (1 J/cm2). Intravenous (iv) administration of conjugate 5b into nude
mice bearing A431 and HT-29 human tumor xenografts resulted in a near-IR fluorescence signal
at ca. 700 nm, 24 h after administration. Our studies show that Pc-EGFR-L1 conjugates are
promising near-IR fluorescent contrast agents for CRC, and potentially other EGFR overexpressing cancers.
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Introduction
Colorectal cancer (CRC) is currently the second leading cause of cancer-related deaths
among both men and women in the US.1 Colon cancer typically develops over several years
and in a linear fashion from adenomatous polyps to carcinoma. Routine colon screening,
detection and removal of polyp adenomas and early stage cancer reduces the incidence of
CRC; however, since the disease lacks outward signs or symptoms, most cancers are
detected at a stage where they may become terminal.2 Current methods of detection for CRC
include flexible sigmoidoscopy, standard colonoscopy, radiography, and computer

1Abbreviations: Pc, phthalocyanine; CRC, colorectal cancer; CLE, confocal laser endomicroscopy; EGFR, epidermal growth factor
receptor; PDT, photodynamic therapy; DMF, dimethylformamide; DMSO, dimethylsulfoxide; THF, tetrahydrofuran; DBN, 1,5diazabicyclo(4.3.0)non-5-ene; DMAE, dimethylaminoethanol; TFA, trifluoroactic acid; DIEA, N,N-diisopropylethylamine; TBTU, 2(1Hbenzotriazol-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate; HATU, 2-(1H-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium
hexafluorophosphate; EDCI, 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide hydrochloride; TEA, triethylamine; Fmoc,
Fluorenylmethyloxycarbonyl; TIS, triisopropylsilane; HOBt, 1-hydroxybenzotriazole; PBS, phosphate buffered saline; FBS, fetal
bovine serum; DMEM, Dulbecco’s modified eagle’s medium; ER, endoplasmic reticulum.
*
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Supporting Information Available: NMR spectra, MS, HPLC chromatograms, phototoxicity and dark toxicity plots, subcellular
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tomography (CT) colonoscopy, which identify large adenoma lesions but frequently miss
small adenomas (< 5 mm) and flat lesions, two early stages of CRC.2 Improvements in the
early detection of small adenomas and flat lesions could prevent the development of
malignant tumors, decreasing mortality and overall health care cost. New detection methods
currently being employed to accomplish this goal include chromoendoscopy, narrow band
imaging, and blue light auto-fluorescence.3 Chromoendoscopy utilizes an absorptive or
contrast dye, such as methylene blue, to stain the mucosa for standard white light
colonoscopy, enhancing tissue characterization, differentiation, and diagnosis of small
adenomas.2, 3 Narrow band imaging uses a blue and green filter to narrow the white
colonoscopic light to illuminate the mucosa, and blue light auto-fluorescence involves a UV
light source to generate mucosal auto-fluorescence. In addition, confocal laser
endomicroscopy (CLE) has been employed to image the mucosa, with fluorescein,
acriflavine, or cresyl violet as the fluorescent dyes. Drawbacks of these dyes are their poor
selectivity for CRC, residual toxicity, and emission wavelengths in the visible region of the
optical spectrum.4 On the other hand, phthalocyanines (Pcs) are tetrapyrrolic macrocycles
with extended π-conjugated systems that typically emit at long wavelengths (> 670 nm)
with relatively high fluorescence quantum yields.5, 6 Advantages of near-IR fluorescence for
bioimaging applications include low Raman scattering cross-sections associated with the use
of low energy excitation photons, larger Raman-free observation windows and reduced
absorption and fluorescence from other compounds.7 Pcs have been extensively investigated
in the last decades for a variety of applications, including as colorant dyes, catalysts,
sensors, and as photosensitizers for photodynamic therapy (PDT) of cancers.8–10 PDT
involves the administration of a photosensitizer followed by activation with red light to
produce cytotoxic oxygen species that destroy malignant cells.11, 12 Due to their low dark
toxicity, high photostability and ability for preferential accumulation within tumor tissue,
Pcs are promising cancer diagnostic and treatment agents. Furthermore, conjugation of Pcs
with peptide ligands directed at specific receptors over-expressed in cancer cells, such as the
human epidermal growth factor receptor (EGFR), is an attractive strategy for increasing
their biological efficacy.13–17 EGFR is over-expressed in CRC, including small cancers (< 5
mm) and the flat, dysplastic, aberrant crypt foci that are believed to precede cancer
development.18–20 Among the EGFR-targeting biomolecules recently reported for selective
delivery of cytotoxic drugs to the tumor sites,21–25 two small peptides with sequences
LARLLT (designated EGFR-L1)26 and YHWYGYTPQNVI (designated EGFR-L2)27 are
particularly attractive due to their readily availability, low immunogenicity, ease of
conjugation to various molecules, and reported superior EGFR-targeting ability. EGFR-L1
was selected from computational screening of an EGFR peptide ligand virtual library, and
shown to target EGFR both in vitro (in EGFR over-expressing H1299 cells) and in vivo (in
H1299 tumor-bearing mice following intravenous (iv) administration).26 On the other hand,
EGFR-L2 was identified from screening of a phage display peptide library and also shown
to bind to EGFR both in vitro (SMMC-7721 cells) and in vivo (SMMC-7721 tumor bearing
mice following iv injection).27 In our continuing investigation of tumor-selective fluorescent
imaging and PDT agents, we have recently shown that a Pc conjugated to a bifunctional
nuclear localizing sequence and cell penetrating peptide containing 32 amino acid residues,
via either a short (5-atom) or a PEG (20-atom) linker, displays higher fluorescence quantum
yield and increased cellular uptake compared with unconjugated Pc.28 We now report the
synthesis, photophysical, and biological evaluation of Pc conjugates to either EGFR-L1 or
EGFR-L2 peptide ligands.
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Experimental Section
1. Chemistry
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All reagents and solvents were purchased from commercial sources and used directly
without further purification. Silica gel 60 (230×400 mesh) and C18 (200×400), both from
Sorbent Technologies, were used for column chromatography. Analytical thin-layer
chromatography (TLC) was carried out using polyester backed TLC plates 254 (precoated,
200 µm) from Sorbent Technologies. NMR spectra were recorded on AV-400 LIQUID
Bruker spectrometer (400 MHz for 1H, 100 MHz for 13C). The chemical shifts are reported
in δ ppm using the following deuterated solvents as internal references: Acetone-d6 2.05
ppm (1H), 29.92 ppm (13C); DMF-d7 8.03 ppm (1H), 163.15 ppm (13C); Pyridine-d5 7.58
ppm (1H), 135.91 ppm (13C). HPLC analyses were carried on a Dionex system equipped
with a P680 pump and UVD340U detector. Absorption spectra were measured on a UV-vis
NIR Scanning Spectrometer, using UV-3101PC SHIMADZU (Cell positioned)–CPS-260
lamp and emission spectra were obtained on a Fluorolog® - HORIBA JOBINVYON (Model
LFI-3751) spectrofluorimeter. MALDI-TOF mass spectra were recorded on a Bruker
ProFlex III mass spectrometer using dithranol as the matrix or Bruker UltrafleXtreme
(MALDI-TOF/TOF) using 4-chloro-α-cyanocinnamic acid as the matrix; high resolution
ESI mass spectra were obtained on an Agilent Technologies 6210 Time-of-Flight LC/MS.
The melting points (mp) were determined using MEL-TEMP electrothermal instrument.
HPLC separation was carried out on a Waters system including a 2545 quaternary gradient
module pump, 2489 UV/Visible detector, and a fraction collector III. Analytical HPLC was
carried out using a XBridge C18 300Å, 5µm, 4.6 × 250 mm (Waters, USA) column using a
stepwise gradient. Semipreparative HPLC was carried out using a XBridge C18 300Å, 5 µm,
10 × 250 mm (Waters, USA) column using a stepwise gradient. The solvent system for
peptides consisted of millipure water and HPLC grade acetonitrile, while it consisted of
millipure water and HPLC grade methanol for the EGFR-L1 conjugates. Pcs 1a,b were
synthesized as previously described.29

$watermark-text

Peptide synthesis and conjugations—Applied Biosystems Pioneer, Peptide Synthesis
System was used to synthesize peptide sequences. Each peptide was synthesized using
Fmoc-PAL-PEG-PS on 0.2 mmol scale using Fmoc strategy of solid-phase peptide
synthesis. A 4-fold excess of the L-Fmoc protected amino acids were coupled using HOBt
and TBTU as the activating agents. The peptide sequences, prepared using this
methodology, were: LARLLT (EGFR-L1) and GYHWYGYTPQNVI (EGFR-L2). Removal
of the Fmoc group from the last amino acid was the final step for each synthesis. This was
followed by washing the peptide several times with DMF/dichloromethane and dried under
high vacuum for 24 h. The Pc-peptide conjugates were synthesized as previously
described.28 In summary, resin containing either GYHWYGYTPQNVI or LARLLT was
dissolved in DMF and soaked for 2 h. The Pcs were dissolved in DMF, the base and
coupling reagents (HOBt and TBTU) added to the Pc solutions. The activated mixture was
transferred into the reaction vessel containing the resin and left to shake for 4 days. The
resin was washed under vacuum several times using DMF, then methanol and finally
dichloromethane. A cleavage cocktail consisting of TFA/phenol/TIS/H2O 88:5:2:5 was
added with constant shaking for 4 h. The solution was washed with TFA (2 × 2 mL) into a
flask and concentrated under vacuum. Cold diethyl ether was added to the residue and the
mixture centrifuged. The Pc-EGFR-L1 conjugates were purified using reverse-phase HPLC
using a Waters system including a 2545 quaternary gradient module pump, 2489 UV/Visible
detector, and a fraction collector III. Analytical HPLC was carried out using a XBridge C18
300 Å, 5 µm, 4.6 × 250 mm (Waters, USA) column with a stepwise gradient. Semipreparative HPLC was carried out using a XBridge C18 300 Å, 5 µm, 10 × 250 mm (Waters,
USA) column with a stepwise gradient. The solvent system consisted of Millipure water and
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HPLC grade methanol (30:70 → 0:100). The purity of the conjugates was > 95% as
determined by HPLC.
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ZnPc 2a—A mixture of Pc 1a (80.0 mg, 0.096 mmol) and 1,4-dioxane-2,6-dione (18.0 mg,
0.16 mmol) was dissolved in DMF (1.0 mL) and the solution stirred overnight at room
temperature. Water (5.0 mL) was added to the solution to precipitate the product. The solid
was filtered under vacuum and washed with water and hexane. The solid was dried under
vacuum for 2 days to afford the pure blue solid (80.4 mg, 86.6%), mp 235 – 236 °C. 1H
NMR (Pyridine-d5): δ 10.78-10.71 (s, 1H, −COOH), 10.17 - 9.41 (m, 7H, Ar-H), 8.44 - 8.23
(m, 6H, Ar-H), 8.01 - 7.71 (m, 3H, Ar-H), 6.04 (br, 1H, N-H), 4.55 (d, J = 12.4 Hz, 2H,
CH2O), 4.47 (d, J = 10.5 Hz, 2H, CH2O), 1.73 – 1.59 (m, 27H, C(CH3)3). 13C NMR
(Pyridine-d5): δ 168.3, 168.2, 156.6, 155.9, 155.8, 154.7, 154.3, 154.0, 152.9, 150.6, 150.4,
150.1, 149.8, 142.4, 140.1, 140.0, 137.8, 137.7, 136.2, 136.0, 135.8, 135.5, 134.3, 134.8,
131.54, 128.46, 128.3, 124.8, 124.2, 124.0, 123.7, 123.4, 122.8, 122.5, 121.4, 120.6, 120.5,
120.4, 120.2, 119.4, 118.1, (Ar-C) 73.1, 70.5 (OCH2), 35.8, 32.4 (Ar-C, C(CH3)3). MS
(MALDI-TOF) m/z 968.319 [M+H]+, calcd for C54H50N9O5Zn 967.323. UV-vis (DMF):
λmax (log ε) 346 nm (5.04), 614 nm (4.80), 680 nm (5.50).
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ZnPc 2b—A mixture of Pc 1b (50.0 mg, 0.06 mmol) and 1,4-dioxane-2,6-dione (11.3 mg,
0.1 mmol) was dissolved in DMF (0.5 mL) and the solution stirred overnight at room
temperature. The mixture was purified as 2a above to afford the pure blue solid (53.5 mg,
92.2%), mp 249 – 250 °C. 1H NMR (Pyridine-d5): δ 10.84-10.77 (s, 1H, −COOH), 10.01 9.35 (m, 8H, Ar-H), 8.50 - 8.21 (m, 5H, Ar-H), 8.10 - 7.90 (m, 1H, Ar-H), 7.54 – 7.41 (m,
2H, Ar-H), 6.74 (br, 1H, N-H), 4.69 (d, J = 5.4 Hz, 2H, CH2O), 4.60 (d, J = 5.6 Hz, 2H,
CH2O), 1.75 – 1.64 (m, 27H, C(CH3)3). 13C NMR (Pyridine-d5): δ 173.9, 168.43, 168.38,
160.0, 159.7, 154.8, 154.7, 154.6, 154.5, 154.3, 153.9, 153.8, 153.5, 153.4, 153.0, 150.6,
150.4, 150.1, 140.8, 139.4, 139.2, 137.0, 136.8, 134.2, 134.0, 131.0, 127.7, 124.7, 122.0,
120.8, 120.7, 120.3, 119.8, 112.5, 111.6 (Ar-C) 72.5, 69.9 (OCH2), 35.8, 31.7 (Ar-C,
C(CH3)3). MS (MALDI-TOF) m/z 968.314 [M+H]+, calcd for C54H50N9O5Zn 968.323.
UV-vis (DMF): λmax (log ε) 351 nm (4.86), 611 nm (4.58), 679 nm (5.33).
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ZnPc 3a—Pc 2a (30.0 mg, 0.032 mmol) was dissolved in DMF (400 ZL). Et3N (4.0 mg,
0.041 mmol), HOBt (4.6 mg, 0.034 mmol) and tert-butyl-12-amino-4,7,10trioxadodecanoate (10.8 mg, 0.039 mmol) were added to the reaction mixture. EDCI (5.3
mg, 0.034 mmol) was then added in one portion. The reaction solution was stirred for 3 days
at room temperature, diluted using ethyl acetate (10 mL) and washed subsequently with
water (20 mL × 2). The organic layer was dried over anhydrous sodium sulfate. The solvent
was evaporated and the crude product purified on silica column eluted with mixed solvents
of DCM/methanol (98:2→ 96:4) to afford a blue solid (30.0 mg, 76.5%). 1H NMR (DMFd7): δ 9.60 - 9.01 (m, 7H, Ar-H), 8.45 - 8.15 (m, 5H, Ar-H), 8.00 – 7.77 (m, 3H, Ar-H), 7.63
– 7.49 (m, 2H, Ar-H), 4.27 – 4.15 (m, 4H, CH2O), 3.62 – 3.57 (m, 3H, CH2O), 3.54 – 3.47
(m, 9H, CH2O), 3.42 – 3.37 (m, 2H, CH2O), 2.44 – 2.39 (m, 2H, CH2CO), 1.82 – 1.78 (m,
27H, C(CH3)3), 1.40 (s, 9H, C(CH3)3). 13C NMR (DMF-d7): δ 171.7, 170.5, 168.8, 168.7,
156.8, 156.2, 155.6, 155.5, 155.2, 155.1, 155.0, 154.7, 154.6, 154.4, 154.3, 154.20, 154.16,
154.0, 153.4, 153.3, 153.2, 152.4, 152.1, 152.04, 151.96, 142.3, 140.03, 139.98, 139.9,
139.6, 137.64, 137.57, 137.5, 137.2, 135.10, 135.06, 143.5, 131.7, 131.6, 130.1, 129.4,
128.7, 128.6, 128.4, 123.6, 123.5, 123.3, 122.6, 122.4, 122.3, 122.0, 120.3, 120.1, 120.0,
119.8, 119.6, 119.0, 118.9, 117.5 (Ar-C), 80.8 (O-C(CH3)3), 72.4, 72.1, 71.20, 71.18, 71.15,
71.1, 71.0, 70.5, 70.32, 70.30, 67.2 (OCH2), 39.64, 39.61, (COCH2), 32.7, 32.6 (Ar-C,
C(CH3)3), 28.5 (N-C(CH3)3). MS (MALDI-TOF) m/z 1170.497 [M-tBu+H]+, calcd for
C63H66N10O9Zn 1170.431. The protected Pc conjugate was dissolved in a mixture of DCM/
TFA (4 mL/4 mL) and stirred at 0° C for 3 h. The solvent was evaporated, the residue

J Med Chem. Author manuscript; available in PMC 2013 April 26.

Ongarora et al.

Page 5

treated with 2N NaOH (2 mL) and then extracted by ethyl acetate (15 mL). The product was
dried under vacuum to afford blue product (24.0 mg, 89.3%), mp 191 – 192 °C. 1H NMR
(DMF-d7): δ 10.15-10.13 (s, 1H, −COOH), 9.59 - 9.08 (m, 7H, Ar-H), 8.42 - 8.10 (m, 5H,
Ar-H), 7.95 - 7.82 (m, 3H, Ar-H), 7.61 – 7.52 (m, 2H, Ar-H), 4.25 – 4.11 (m, 4H, CH2O),
3.79–3.57 (m, 12H, CH2O), 3.41–3.37 (m, 2H, CH2O), 2.51–2.48 (m, 2H, CH2CO), 1.79 (s,
27H, C(CH3)3). 13C NMR (Pyridine-d5): δ 173.7, 170.5, 168.7, 156.9, 156.2, 155.4, 154.5,
153.7, 152.6, 145.6, 142.6, 140.2, 139.8, 137.6, 135.2, 134.6, 131.7, 128.7, 123.5, 122.7,
122.4, 120.0, 119.1, 117.7 (Ar-C), 72.5, 72.2, 71.3, 70.4, 67.8 (OCH2), 35.5 (COCH2), 32.6
(Ar-C, C(CH3)3). MS (MALDI-TOF) m/z 1170.485 [M]+, calcd for C63H66N10O9Zn
1170.431. UV-vis (DMF): λmax (log ε) 349 nm (4.90), 612 nm (4.61), 678 nm (5.35).
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ZnPc 3b—Pc 2b (30.0 mg, 0.032 mmol) was dissolved in DMF (400 ZL). Et3N (4.0 mg,
0.041 mmol), HOBt (4.6 mg, 0.034 mmol) and tert-butyl-12-amino-4,7,10trioxadodecanoate (10.8 mg, 0.039 mmol) were added to the reaction solution and the
solution was stirred for 20 min. EDCI (5.3 mg, 0.034 mmol) was added to the reaction
solution in one portion. The reaction was then treated as 3a above to afford a blue solid
(32.2 mg, 82.3%). 1H NMR (Acetone-d6): δ 9.87 - 9.77 (m, 1H, Ar-H), 9.07 – 7.40 (m, 16H,
Ar-H), 3.99 (s, 2H, CH2O), 3.87 (s, 2H, CH2O), 3.58 – 3.54 (m, 2H, CH2O), 3.45 (s, 8H,
CH2O), 3.38 (s, 2H, CH2O), 3.22 (s, 2H, CH2O), 2.36 – 2.33 (m, 2H, CH2CO), 1.88 – 1.78
(m, 27H, C(CH3)3), 1.37 (s, 9H, C(CH3)3). 13C NMR (DMF-d7): δ 171.8, 170.7, 169.3,
169.2, 162.4, 160.8, 160.4, 155.0, 154.8, 154.3, 154.2, 141.4, 140.0, 139.8, 137.6, 136.7,
136.4, 134.5, 128.6, 125.2, 123.4, 123.0, 121.4, 121.3, 120.9, 120.0, 112.8, 111.7 (Ar-C),
81.0 (O-C(CH3)3), 72.6, 72.4, 71.5, 71.43, 71.36, 71.3, 70.6, 67.8 (OCH2), 32.8 (Ar-C,
C(CH3)3), 28.7 (N-C(CH3)3). MS (MALDI-TOF) m/z 1227.682 [M+H]+, 1170.495 [M−tBu
+H]+, calcd for C67H75N10O9Zn 1227.501, C63H66N10O9Zn 1170.431. The protected Pc
conjugate was then deprotected as 3a above to afford a blue solid (25.3 mg, 88.3%), mp 161
– 163 °C. 1H NMR (DMF-d7): δ 10.42-10.33 (s, 1H, COOH), 9.57 - 9.32 (m, 6H, Ar-H),
9.09 - 8.75 (m, 1H, Ar-H), 8.55 - 8.20 (m, 4H, Ar-H), 8.15 - 8.00 (m, 2H, Ar-H), 7.99 – 7.81
(m, 1H, Ar-H), 7.65 – 7.50 (m, 2H, Ar-H), 4.36 (d, J = 7.2 Hz, 2H, CH2O), 4.28 (d, J = 5.1
Hz, 2H, CH2O), 3.65 – 3.57 (m, 12H, CH2O), 3.41 – 3.37 (m, 2H, CH2O), 2.55 – 2.48 (m,
2H, CH2O), 1.85 – 1.74 (m, 27H, C(CH3)3). 13C NMR (DMF-d7): δ 173.7, 170.6, 169.2,
169.1, 160.64, 160.58, 160.25, 160.18, 155.3, 155.22, 155.16, 155.1, 155.0, 154.9, 154.8,
154.7, 154.3, 154.2, 1154.15, 154.11, 153.0, 153.9, 153.4, 153.3, 153.2, 153.1, 141.5, 141.4,
140.1, 140.0, 139.8, 137.7, 137.64, 137.55, 137.5, 136.5, 136.2, 134.8, 134.7, 134.6, 128.3,
128.2, 126.2, 125.0, 123.3, 123.2, 122.8, 122.0, 121.2, 121.11, 121.06, 120.8, 120.7, 119.9,
119.8, 112.7, 111.6, (Ar-C), 72.4, 72.1, 71.28, 71.25, 71.14, 71.10, 70.4, 68.3, 67.7 (OCH2),
39.7, 36.8 (COCH2), 32.6 (Ar-C, C(CH3)3). MS (MALDI-TOF) m/z 1170.508 [M]+, calcd
for C63H66N10O9Zn 1170.431. UV-vis (DMF): λmax (log ε) 350 nm (4.65), 610 nm (4.41),
676 nm (5.19).
ZnPc conjugate 4b—Resin (60.0 mg) containing 0.0052 mmol GYHWYGYTPQNVI
was transferred into a reaction vial. DMF was added (5:1, DMF/resin) and soaked for 2 h.
The resin was washed four times with DMF. Pc 2b (10.0 mg, 0.010315 mmol) was weighed
into a vial and DMF (200 µL) added. Then HOBt (1.4 mg, 0.010315 mmol), TBTU (3.3 mg,
0.010315 mmol) and DIEA (5.39 µL, 0.030946 mmol) were added to the Pc solution. The
mixture was stirred for 30 min, transferred into the vial containing the resin and left to shake
for 3 days. The resin was washed under vacuum using DMF (till DMF was clear), followed
by methanol and finally DCM. A cleavage cocktail – TFA/phenol/TIS/H2O (88:5:2:5) – was
added and shaken constantly for 4 h. The solution was then washed with TFA (2 × 2 mL)
into a 50 mL flask under vacuum. Cold diethylether was added to the residue and the
mixture centrifuged. The precipitate was then sonicated in water and centrifuged several
times to give the title compound (9.2 mg, 35.0%), mp 211 – 212 °C. 1H NMR (DMF-d7): δ
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9.51-9.20 (m, 5H, Ar-H), 8.45-8.10 (m, 9H, Ar-H), 7.80-7.75 (m, 2H, Ar-H), 7.70-7.50 (m,
2H, Ar-H), 7.35-7.20 (m, 24H, Ar-H), 7.07-6.91 (m, 14H, Ar-H), 6.80-6.70 (m, 4H, Ar-H),
6.65-6.53 (m, 9H, Ar-H), 4.68-4.30 (m, 12H, CH2NH), 4.24-3.65 (m, 4H, CH2O/CH2NH),
3.45-3.30 (m, 4H, CH2O/CH2NH), 2.25-2.04 (m, 2H, CH2CO), 2.01-1.75 (m, 21H,
C(CH3)3/CH2), 1.33 (s, 5H, , CH3), 1.26 (s, 2H, CH2), 1.18-1.10 (m, 4H, CH2), 1.00-0.94
(m, 8H, CH2), 0.85-0.75 (m, 18H, CH3). MS (MALDI-TOF) m/z 2545.04 [M]+, calcd for
C131H148N28O23Zn 2545.0563. UV-vis (DMF): λmax (log ε) 351 nm (4.44), 610 nm (4.07),
677 nm (4.87).
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ZnPc conjugate 5a—Resin (25.7 mg, 0.0052 mmol) containing LARLLT, was
transferred into a reaction vial. DMF was added (5:1, DMF/resin) and left to soak for 4 h,
after which it was washed four times with DMF. Pc 3a (10.0 mg, 0.010315 mmol) was
weighed into a 2.0 mL vial and DMF (200 µL) added. DIEA (6.4 ZL, 0.036745 mmol) was
added to the solution and stirred for 1 h. Then HOBt (1.8 mg, 0.013321 mmol), HATU (4.0
mg, 0.010521 mmol) were added to the Pc solution. The mixture was added to the resin and
left to shake for 4 days and cleaved as described above for Pc 4b. The product was purified
using reverse-phase HPLC eluted by water/methanol (30:70 → 0:100) to afford a blue solid
(7.6 mg, 79.2%), mp 151–152 °C. 1H NMR (DMF-d7): δ 10.18, 10.13 (s, 1H, N-H),
9.67-9.20 (m, 5H, Ar-H), 8.55-8.45 (m, 3H, Ar-H), 8.25-8.15 (m, 2H, Ar-H), 8.13-8.05 (m,
1H, Ar-H), 7.97-7.86 (m, 5H, Ar-H), 7.85-7.79 (m, 2H, Ar-H), 7.61-7.47 (m, 5H, Ar-H),
7.20 (s, 1H, Ar-H), 7.13 (s, 1H, Ar-H), 4.39-4.01 (m, 26H, CH2O/CH2NH), 3.77-3.70 (m,
3H, CH2O), 3.56-3.50 (m, 12H, CH2O), 3.43-3.31 (m, 3H, CH2O), 2.55-2.41 (m, 2H,
CH2CO), 2.01-1.92 (m, 3H, CH2), 1.85-1.71 (m, 27H, C(CH3)3/7H, CH2), 1.69-1.62 (m,
3H, CH2), 1.43-1.35 (m, 4H, CH2), 1.21-1.15 (m, 4H, CH2), 0.94-0.87 (m, 20H, CH3). 13C
NMR (DMF-d7): δ 175.5, 175.3, 174.10, 174.07, 173.7, 173.4, 170.5, 168.8, 168.7, 160.3,
159.9, 158.7, 156.8, 156.2, 155.6, 155.3, 155.1, 154.4, 152.4, 152.1, 140.0, 137.9, 137.6,
135.1, 134.5, 131.7, 128.6, 123.4, 122.6, 122.4, 120.0, 119.0, 117.5, 116.1 (Ar-C), 72.3,
72.0, 71.3, 71.2, 71.0, 70.9, 70.3, 68.2, 68.0, 66.3 (OCH2), 60.1, 55.2, 54.6, 54.0, 53.5. 51.8,
41.9, 41.3, 41.2, 39.5, 37.2 (CH2) 32.6 (Ar-C, C(CH3)3), 29.4, 26.5, 25.6, 25.5, 24.0, 23.8,
23.5, 22.3, 22.0, 21.8, 20.7, 17.5 (CH3). MS (MALDI-TOF) m/z 1837.907 [M+H]+, calcd
for C94H125N20O15Zn 1837.892. MS-MS (MALDI-TOF-TOF) m/z 1839.90 [PcPEGLARLLT+H]+, 1822.88 [PcPEG-LARLLT-NH2+H]+, 1794.88 [PcPEG-LARLLTCONH2+H]+, 1723.042 [PcPEG-LARLL-NH2+H]+, 1580.75 [PcPEG-LARL-CO+H]+,
1339.56 [PcPEG-LA-NH2+H]+, 1268.52 [PcPEG-L-NH2+H]+, 1240.53 [PcPEG-L-CO
+H]+, 1155.44 [PcPEG-NH2+H]+, calcd for C94H125N20O15Zn 1837.892,
C94H124N19O15Zn 1822.882, C93H124N19O14Zn 1794.887, C90H117N18O13Zn 1721.834,
C83H106N17O11Zn 1580.755, C72H83N12O10Zn 1339.565, C69H78N11O9Zn 1268.528,
C68H78N11O8Zn 1240.533, C63H67N10O8Zn 1155.444. UV-vis (DMF): λmax (log ε) 348
nm (4.79), 612 nm (4.56), 680 nm (5.33).
ZnPc conjugate 5b—Resin (25.7 mg, 0.0052 mmol) containing LARLLT, was
transferred into a reaction vial. DMF was added (5:1, DMF/resin) and left to soak for 4 h,
after which it was washed four times with DMF. Pc 3b (10.0 mg, 0.010315 mmol) was
weighed into a 2.0 mL vial and DMF (200 µL) added. DIEA (6.4 ZL, 0.036745 mmol) was
added to the solution and stirred for 1 h. Then HOBt (1.8 mg, 0.013321 mmol), HATU (4.0
mg, 0.010521 mmol) were added to the Pc solution. The mixture was added to the resin and
left to shake for 4 days. It was then cleaved and purified using reverse-phase HPLC eluted
by water/methanol (30:70 → 0:100) to afford a blue solid (8.1 mg, 84.4%, mp 167 – 168
°C). 1H NMR (DMF-d7): δ 10.40, 10.35 (s, 1H, N-H), 9.67-9.20 (m, 5H, Ar-H), 8.57-8.45
(m, 3H, Ar-H), 8.30-8.25 (m, 2H, Ar-H), 8.13-8.05 (m, 2H, Ar-H), 7.97-7.86 (m, 3H, Ar-H),
7.85-7.79 (m, 2H, Ar-H), 7.61-7.47 (m, 5H, Ar-H), 7.18 (s, 1H, Ar-H), 7.12 (s, 1H, Ar-H),
4.37 (d, J = 7.6, 4H, CH2O), 4.29-4.21 (m, 9H, CH2NH), 3.77-3.70 (m, 16H, CH2NH),
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3.65-3.57 (m, 12H, CH2O), 3.54-3.43 (m, 2H, CH2NH), 3.37-3.29 (m, 3H, CH2NH),
2.61-2.56 (m, 2H, CH2CO), 2.01-1.92 (m, 2H, CH2), 1.91-1.71 (m, 27H, C(CH3)3/7H,
CH2), 1.69-1.58 (m, 5H, CH2), 1.39-1.36 (m, 4H, CH2), 1.17-1.15 (m, 4H, CH2), 0.95-0.86
(m, 20H, CH3). 13C NMR (DMF-d7): δ 175.5, 175.3, 174.1, 174.0, 173.7, 173.6, 173.4,
170.6, 169.2, 169.1, 160.2, 159.9, 158.8, 154.6, 154.2, 153.7, 140.2, 139.8, 136.7, 136.3,
128.6, 128.4, 122.8, 122.2, 121.4, 120.9, 119.3, 116.3 (Ar-C), 72.4, 72.2, 71.3, 71.1, 71.0,
70.4, 68.2, 68.1, 66.3 (OCH2), 60.1, 55.2, 54.6, 54.0, 53.5. 51.8, 41.9, 41.34, 41.29, 39.7,
37.2 (CH2) 32.6 (Ar-C, C(CH3)3), 29.4, 26.5, 25.7, 25.6, 25.5, 24.0, 23.8, 23.5, 22.4, 22.0,
21.8, 20.7, 17.6 (CH3). MS (MALDI-TOF) m/z 1837.925 [M+H]+, calcd for
C94H125N20O15Zn 1837.892. MS-MS (MALDI-TOF-TOF) m/z 1839.90 [PcPEG-LARLLT
+ H]+, 1822.88 [PcPEG-LARLLT-NH2+H]+, 1794.88 [PcPEG-LARLLT-CONH2+H]+,
1721.83 [PcPEG-LARLL-NH2+H]+, 1580.75 [PcPEG-LARL-CO+H]+, 1339.56 [PcPEGLA-NH2+H]+, 1268.52 [PcPEG-L-NH2+H]+, 1240.53 [PcPEG-L-CO+H]+, 1155.44
[PcPEG-NH2+H]+, calcd for C94H125N20O15Zn 1837.892, C94H124N19O15Zn 1822.882,
C93H124N19O14Zn 1794.887, C90H117N18O13Zn 1721.834, C83H106N17O11Zn 1580.755,
C72H83N12O10Zn 1339.565, C69H78N11O9Zn 1268.528, C68H78N11O8Zn 1240.533,
C63H67N10O8Zn 1155.444. UV-vis (DMF): λmax (log ε) 352 nm (4.79), 610 nm (4.52), 677
nm (5.29).
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ZnPc conjugate 6a—Resin (60.0 mg, 0.0052 mmol) containing GYHWYGYTPQNVI
was transferred into a reaction vial. DMF was added (5:1, DMF/resin) and left to soak for
one hour, after which it was washed four times with DMF. Pc 3a (12.1 mg, 0.010315 mmol)
was weighed into a 2.0 mL vial and DMF (200 µL) added. Then HOBt (1.4 mg, 0.010315
mmol), HATU (3.9 mg, 0.010315 mmol) and DIEA (5.39 µL, 0.030946 mmol) were added
to the Pc solution. The mixture was stirred for five minutes, transferred into the reaction
chamber containing the resin and left to shake for 3 days. Cleavage from solid support and
purification proceeded as described above for Pc 4b to afford a blue solid (11.5 mg, 40.5%,
mp 208 – 209 °C). 1H NMR (DMF-d7): δ 10.40, 10.35 (s, 1H, COOH), 9.51-9.20 (m, 6H,
Ar-H), 8.45-8.10 (m, 10H, Ar-H), 7.80-7.75 (m, 2H, Ar-H), 7.70-7.50 (m, 2H, Ar-H),
7.45-7.20 (m, 30H, Ar-H), 7.15-6.95 (m, 14H, Ar-H), 6.90-6.78 (m, 4H, Ar-H), 6.74-6.65
(m, 9H, Ar-H), 4.75-4.10 (m, 16H, CH2O/CH2NH), 4.04-3.65 (m, 7H, CH2O/CH2NH),
2.25-2.04 (m, 6H, CH2CO), 2.01-1.75 (m, 21H, C(CH3)3/CH2), 1.43 (s, 4H, , CH2), 1.31 (s,
3H, CH2), 1.21-1.15 (m, 4H, CH2), 1.05-1.00 (m, 8H, CH2), 0.94-0.85 (m, 19H, CH3). MS
(MALDI-TOF) m/z 2748.17 [M]+, calcd for C140H165N29O27Zn 2748.1723. MS-MS
(MALDI-TOF-TOF) m/z 2751.19 [PcPEG-GYHWYGYTPQNVI]+, 2733.25 [PcPEGGYHWYGYTPQNVI-NH2]+, 2702.25 [Pc-PEGGYHWYGYTPQNVI-CONH2]+, 2165.86
[PcPEG-YHWYGYT-NH2-OH]+, 1670.78 [PcPEG-GYHW-CONH2]+, 1490.70. [PcPEGGYH-CONH2]+, 1346.53 [Pc-PEG-GY-CONH2]+, 1226.34 [PcPEG-G]+, 1155.44 [PcPEGNH2+H]+, calcd for C140H165N29O27Zn 2748.17, C140H164N28O27Zn 2733.16,
C139H164N28O26Zn 2705.17, C115H123N21O19Zn 2165.86, C90H95N17O12Zn 1669.66,
C79H85N15O11Zn 1483.58, C73H78N12O10Zn 1346.53, C65H70N12O9Zn 1226.47,
C63H67N10O8Zn 1155.44. UV-vis (DMF): λmax (log ε) 345 nm (3.84), 612 nm (4.25), 680
nm (4.60).
2. Spectroscopic studies
All absorption spectra were measured on UV-VIS NIR Scanning Spectrometer UV-3101PC
SHIMADZU (Cell positioned) equipped with a CPS-260 lamp. The DMF solvent used was
HPLC grade and it was the solvent of choice since it dissolved all the Pcs relatively good.
Stock solutions (1000 ZM, 1.0 mL) of all Pcs were prepared and the dilutions were prepared
by spiking 20 – 80 ZL of the corresponding stock solution into 10.0 mL of solvent. Emission
spectra were obtained on a Fluorolog®-HORIBA JOBINVYON (Model LFI-3751)
spectrofluorimeter. The optical densities of the solutions used for emission studies ranged
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between 0.04 – 0.05 at excitation wavelengths. All experiments were carried out within 4 h
of solution preparation at room temperature (23–25 °C) with 10 mm path length
spectrophotometric cell. The fluorescent quantum yields (Фf) were determined using a
secondary standard method.30 By comparison with ZnPc (Фf = 0.17) as a reference, the
values of fluorescence were obtained in DMF solvent.31
3. Computational and SPR studies
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Docking of EGFR-L1, L2 peptides and their conjugates to EGFR protein extracellular
domain was performed using AUTODOCK 4 software.32, 33 EGFR crystal structure was
obtained from a protein databank (PDB code: 1nql).34 Solvent molecules were removed
from the pdb file. Polar hydrogen atoms were added to the structure. Three dimensional
structures of peptides and their conjugates, EGFR-L1, EGFR-L2, 4b, 5b and 6a were
generated using InsightII (Accelrys Inc., Sandiego, CA). Structures were subjected to 300 K
and molecular dynamics (MD) followed by simulated annealing MD.35 The final structure
from simulated MD was energy minimized and used for docking studies. A grid box with
dimensions of 128×128×128 Å3 was used for calculations. For EGFR-L1 peptide and 5b
docking a grid box was created with amino acid residue on EGFR Asn134 as center of the
grid box, and for EGFR-L2, 4b and 6a docking a grid box was created near the EGF binding
site on EGFR.26, 27 For 4b, 5b and 6a, the zinc atom was included in addition to the atom
types of the peptide/protein for grid calculations. In all these ligand molecules rotatable
bonds were allowed to rotate during docking calculations. For docking, 50 runs with 10
million energy evaluations were carried out using Lamarkian genetic algorithm. Docking
calculations were performed on Linux cluster on high performance supercomputers at LSU
Baton Rouge. Docked structures were listed in increasing order of energy, and low energy
clusters were used as the most probable binding models. The energy reported is for the
lowest energy docked structure from a cluster of conformations. Structures from low energy
docking were displayed and analyzed using PyMol software.
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The surface plasmon resonance (SPR) experiments were performed using Biacore X100 (GE
Health Sciences) at 25 °C.36, 37 Immobilization of EGFR (obtained from Leinco
Technologies, St. Louis, MO), was performed by standard amine coupling procedure on a
CM5 chip. The carboxyl groups on the sensor chip were activated by a solution containing
0.2 M N-ethyl-N-(dimethylaminopropyl) carbodiimide and 0.05 M N-hydroxysuccinimide
(35 ZL solution, flow rate 5 ZL/min). Running buffer consisted of 0.01 M HEPES, 0.15 M
NaCl, 3 mM EDTA, 0.005% Tween at pH 7.5. Regeneration buffers were 50% acid cocktail
and glycine 100 mM at pH 2.5. The EGF ligand was obtained from Abcam, Inc.
(Cambridge, MA).
4. Cell Studies
All tissue culture medium and reagents were purchased from Invitrogen (Carlsbad, CA).
Human carcinoma HEp2 cells, human epidermoid carcinoma A431, human colorectal
adenocarcinoma HT-29, and cercopithecus aethiops kidney Vero cells, were purchased from
ATCC. HT-29 cells were cultured and maintained in McCoy’s 5a Medium Modified
supplemented with 10% FBS and 1% antibiotic (Penicillin Streptomycin). HT-29 cells were
infected with a lentivirus containing the enhanced green fluorescent protein (eGFP; virus
purchased from Biogenova, Ellicott City, MD). Green fluorescent cells were sorted by flow
cytometery and expanded to generate a line termed “HT-29 eGFP”. Both A431 and Vero
cells were cultured and maintained in ATCC formulated DMEM supplemented with 10%
FBS and 1% antibiotic (Penicillin Streptomycin). HEp2 cells were cultured and maintained
in 50:50 ATCC formulated DMEM/Advanced MEM containing 10% FBS and 1% antibiotic
(Penicillin Streptomycin). The cells were split twice weekly to maintain a sub-confluent
stock. All compound solutions were filter-sterilized using a 0.22 µm syringe filter. A 32 mM
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stock solution was prepared for each Pc by dissolving in DMSO containing 5% Cremophor
EL (as a nonionic emulsifier), to avoid compound precipitation upon dilution into media.
From this solution, a 400 µM stock was also prepared in desired medium and filter-sterilized
using a 0.22 µm syringe filter.
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4.1. Time-Dependent Cellular Uptake—HEp2 cells and A431 cells were plated at
7,500 per well in a Costar 96 well plate and allowed to grow for 48 h. Vero cells were plated
at 7,500 per well in a Costar 96 well plate and allowed to grow for 24 h. HT-29 cells were
plated at 7,500 per well in a Costar 96 well plate and allowed to grow for 96 h. Pc stock
solutions (32 mM) were diluted to 10 µM Pc solutions in media and added to the cells at
different time periods of 0, 1, 2, 4, 8, and 24 h. Uptake of the compounds was stopped by
removing loading medium and washing once with PBS. Cells were solubilized by adding
0.25% Triton X-100 in PBS. The Pc concentration was determined by reading its
fluorescence emission at 650/700 nm (excitation/emission) using a BMG FLUOstar plate
reader (Cary, NC). Cell number was quantified using CyQuant reagent.
4.2. Dark Cytotoxicity—The cells were plated and allowed to grow as described above.
Pc stock solutions (32 mM) were diluted to concentrations of 25, 50, 100 and 125 µM in
medium, and added to cells for 24 h. The loading medium was removed and medium
containing Cell Titer Blue was added to determine the toxicity of the compounds (viable
cells were measured fluorescently at 570/615 nm); untreated cells were considered 100%
viable and cells treated with 0.2% saponin as 0% viable.
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4.3. Phototoxicity—The cells were plated and allowed to grow as described above. Pc
stock solutions (32 mM) were diluted to concentrations of 6.25, 12.5, 25, 50 and 100 µM in
medium and added to cells for 24 h. The loading medium was removed and fresh medium
was added. The conjugates were exposed to light for 20 min using a light system (Newport)
for a light dose of ~ 1 J/cm2. The plates were chilled at 5 °C using a cooling block. Water
was used as a filter for IR radiation. The plates were then incubated for another 24 h
followed by removing medium and adding medium containing Cell Titer Blue to determine
the toxicity of the compounds.
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4.4. Microscopy—The cells were inoculated in a glass-bottom 6-well plate (MatTek) and
allowed to grow for 48 h. The cells were then exposed to 10 µM for each Pc for 6 h.
Organelle tracers were obtained from Invitrogen and used at the following concentrations:
LysoSensor Green 50 nM, MitoTracker Green 250 nM, ER Tracker Blue/white 100 nM, and
BODIPY FL C5 ceramide 1 µM. Images were acquired using a Leica DMRXA microscope
with 40× NA 0.8dip objective lens and DAPI, GFP and Texas Red filter cubes (Chroma
Technologies).
5. In Vivo uptake studies
For the animal studies, Nu/nu mice were purchased from Charles Rivers Laboratories at 6
weeks of age. After approximately 2 weeks of quarantine, mice were implanted with tumor
cells subcutaneously in the upper flank. For these injections, each cell line was cultured to
approximately 75% confluence, then dissociated with trypsin, and concentrated by
centrifugation. Since the two tumor lines were found to grow at different rates in nude mice,
1 × 106 A431 cells and 2 × 106 HT-29 eGFP cells were implanted in a volume of 100 µL.
The injection material consisted of 4 parts DMEM and 1 part MatriGel basement membrane
matrix (BD biosciences). Tumors were allowed to develop until palpable (approximately 6
days for A431 cells and 9 days for HT-29 eGFP cells), after which mice were imaged for
time = 0, then injected through the tail vein with 20 µL of a 10 mM solution of Pc 5b in 10%
DMSO and 5% Cremophor EL in PBS, for a dose of ~ 10 mg/kg. The mice were then
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observed for acute adverse responses to the injected Pc and returned to their box until
imaged. Prior to imaging at selected time points after Pc administration, mice were
anesthetized with isoflurane gas to effect then imaged individually for 30 s at excitation 630
nm and emission 700 nm (x630/m700) in a Kodak In Vivo FX whole animal imager. All
animal experiments were conducted by adherence to a protocol approved by the LSU
IACUC committee.
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To rule out toxicity related to the concentration of DMSO (10%) and Cremophor EL (5%)
used to solubilize the conjugates, an additional viability assay was performed in vitro to
estimate cancer tissue exposure in vivo (see Supporting Information for details). Addition of
DMSO and Cremophor EL to culture media at either blood volume or extracellular fluid
volume dilutions showed no effect on cell viability over a 96 h period suggesting it is
unlikely that these agents resulted in toxicity in vivo after dilution and distribution.
To quantify relative fluorescence within the image of the tumor region, a region-of-interest
(roi) was drawn around the tumor and the mean pixel intensity (mpi) of this roi was divided
by the mpi’s of 3 adjacent skin areas to obtain a percent of tumor fluorescence over adjacent
regions. In order to visually distinguish one roi as more fluorescent than adjacent skin, we
found that the roi needed to be at least 120%.
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At 24 and 96 h following iv injection of Pc 5b, the HT-29 tumor tissue was harvested from
mice and flash frozen. The tissue was kept in 5 mL of acetone/methanol (5:1) at -20 °C
overnight, then crushed repeatedly using a mortar, filtered and the organic solvents removed
under reduced pressure. The residues were analyzed by MS-MALDI-TOF and UV-Vis
spectrophotometry. Frozen sections of tumor were cut to 10 µm thickness and mounted on
glass slides. Tissues were immediately imaged for both eGFP indicating regions of HT-29
tumor and near-IR indicating Pc fluorescence using Chroma 41017 (450–490 nm excitation,
500–550 nm emission) and Omega Optical 140-2 (570–645 nm excitation, 668–723 nm
emission) filter sets respectively.

Results and Discussion
1. Synthesis and characterization
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The Pc-peptide conjugates described in this study were designed to specifically target
EGFR. The synthetic route to conjugates 4b, 5a, 5b and 6a is shown in Scheme 1. Pcs 1a,b
were prepared by statistical condensation of 3- or 4-(p-N-Boc-aminophenoxy)phthalonitrile
and 4-tert-butylphthalonitrile (in 1:3 ratio) in DMAE at 140 °C for 5 h, and in the presence
of Zn(II) acetate and DBN, followed by TFA deprotection of the Boc groups, as we have
previously described.29 Reaction of Pcs 1a,b with diglycolic anhydride in DMF gave the
corresponding α- or β-substituted carboxy-terminated Pcs 2a,b, respectively, in 87–92%
yields.28, 38 The coupling of Pcs 2a,b with commercially available tert-butyl protected PEG
using HOBt, EDCI and DIEA, following by deprotection of the tert-butyl group afforded the
Pcs 3a,b in 68–73% overall yields;38 lower yields were obtained when TBTU was used in
place of EDCI, due to a more difficult purification of the target Pc-PEG compounds. Solidphase conjugation of Pcs 2b, 3a and 3b to the two peptide sequences LARLLT26 (EGFRL1) and GYHWYGYTPQNVI27 (EGFR-L2) using DIEA, HOBt and TBTU or HATU in
DMF and at room temperature, gave the targeted Pc-peptide conjugates 4b, 5a, 5b and 6a in
20–80% yields, after deprotection and cleavage from the solid support, followed by
reversed-phase chromatographic purification. A glycine residue was added to the Nterminus of the EGFR-L2 peptide in order to increase the conjugation reaction yields.38, 39
EGFR over-expression has been found in a variety of human cancers, including breast,
ovarian, prostate, pancreatic, and colorectal;40 for this reason EGFR has been an important
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target for cancer treatment.13–17 Monoclonal antibodies (mAbs), such as cetuximab and
trastuzumab, and tyrosine kinase inhibitors (TKIs), such as erlotinib and gefitinib, are
HER1/EGFR-targeted agents currently in clinical development, or already approved, for use
in several countries. Peptides EGFR-L1 and EGFR-L2 were designed to act as a substitute
for the natural ligand EGF, which has reported mitogenic and neoangiogenic activity, and
has been shown to specifically target EGFR over-expressing tumor cells both in vitro and in
vivo.26, 27 Advantages of using small peptide ligands as target units are their easy synthesis
and coupling to fluorophores, and their low immunogenicity and high binding affinity for
the biological target. We have previously conjugated a Pc macrocycle to a lysine-rich
bifunctional peptide sequence containing 32 amino acid residues, via a similar short (5atom) and a long (20-atom) PEG linker, and observed that the PEG linker increased cellular
uptake into human HEp2 cells, and decreased cytotoxicity of the Pc conjugate.28 On the
other hand, the short linker Pc conjugate showed higher fluorescence quantum yield,
probably as a result of its lower conformational flexibility compared with the PEG group. In
the present study we investigated a short (5-atom) and a low molecular weight PEG (13atom) linkers between the Pc and the peptide ligand; the smaller PEG group has the
advantages of being commercially available and potentially less flexible than the
penta(ethylene glycol) previously used. In addition, the PEG linker is believed to favor an
extended conformation for conjugates 5a,b and 6a,38 which might favor EGFR target
binding, and to increase their aqueous solubility compared with conjugate 4b (vide infra).
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All Pcs were characterized by MS, NMR, UV-Vis and fluorescence spectroscopy; MALDITOF was used to confirm the amino acid sequence in the Pc-peptide conjugates (see
Supporting Information, Figures S22–S52). The spectroscopic properties for Pcs 3a,b, 4b,
5a,b and 6a are summarized in Table 1 and Figure S18 of the Supporting Information). All
Pcs showed strong Q absorption bands between 677 – 680 nm in DMF, and emissions
between 680 – 683 nm in the same solvent, with fluorescence quantum yields in the range
0.10–0.13 and Stokes’ shifts of 2 – 4 nm, characteristic of this type of compound.28, 29 All
Pc-peptide conjugates are soluble in polar organic solvents, such as DMSO and DMF, up to
1.0 mM concentrations, however precipitation was observed upon dilution into aqueous
solutions. Therefore, Cremophor EL, a non-ionic solubilizer and emulsifier, was added to all
Pc stock solutions used in the biological and EGFR-binding experiments; the cell studies
were conducted in PBS/DMSO/Cremophor (94:1:5) and the mice studies in PBS/DMSO/
Cremophor (85:10:5). No toxic effects were observed in vitro nor in vivo from these
amounts of DMSO and Cremophor EL (see Figure S57 of the Supporting Information).
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The solubility of the Pcs decreased in the order Pc-PEG (3a,b) > Pc-EGFR-L1 (5a,b) > PcEGFR-L2 (6a) > Pc-EGFR-L2 (4b), due to the high hydrophobicity of the longer EGFR-L2
sequence (containing 11 hydrophobic amino acids and only two polar), compared with
EGFR-L1 (containing 4 hydrophobic amino acids, one polar and one cationic). Indeed, the
uncharged Pc conjugates 4b and 6a showed decreased solubility in polar protic solvents
such as methanol, compared with the positively charged Pc conjugates 5a,b. The least
soluble was the Pc-EGFR-L2 conjugate 4b bearing a short 5-atom linker.
2. Docking and binding studies
To model the interaction of peptides EGFR-L1 and EGFR-L2 and their Pc conjugates with
EGFR docking studies were carried out using Autodock.32, 33 EGFR-L1 is known to bind to
a pocket away from the EGF binding pocket in EGFR,26 while EGFR-L2 binds to the EGF
binding pocket.27 Hence, for EGFR-L1 grid box for docking calculations were around
Glu71, Asn134, Gly177. The low energy docked structure (docking energy of -6.06 kcal/
mol) of EGFR-L1 is shown in Figure 1a. The Leu4 backbone carbonyl and Thr6 side chain
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hydroxyl groups form hydrogen-bonding interaction with EGFR. The RLLT sequence of the
peptide acquired a β-turn conformation when bound to the receptor EGFR.
The low energy docked structure of EGFR-L2 peptide is shown in Figure 1b. EGFR-L2
peptide binds to EGF binding pocket with docking energy of -5.96 kcal/mol. Tyr1 and Ile12
residues from the peptide formed hydrogen-bonding interactions with the EGFR stabilizing
the peptide-receptor interaction. Overall, the peptide did not have any particular secondary
structure as shown in the Figure 1b. Peptide was bound in the cavity of EGF binding pocket
of EGFR. These results indicate that both peptides EGFR-L1 and EGFR-L2 can bind to
EGFR.

$watermark-text
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To evaluate the effect of conjugation on binding to EGFR and the linker size, docking
studies were performed on Pc conjugates 4b, 5b and 6a. In Pc-EGFR-L2 4b the peptide is
conjugated via a short (5-atom) linker, in 6a via 13-atom PEG linker, while in Pc-EGFR-L1
5b the peptide is conjugated via 13-atom PEG linker. Docking of 4b and 6a were similar to
that of EGFR-L2 (see Figure S55 of the Supporting Information). However, the docking
energies obtained for conjugates 4b and 6a were lower (with a docking intermolecular
energy of −17 kcal/mol for 4b and -8 kcal/mol for 6a) than that of peptide EGFR-L2 alone
(−6 kcal/mol). Conjugates 4b and 6a were docked to the EGF binding site, with the Pc
macrocycle extending outside the EGF binding pocket and anchoring near the hydrophobic
region around amino acid residues Tyr89, Tyr93 and Phe148 of EGFR. On the other hand,
Pc-EGFR-L1 conjugate 5b showed lower docking energy (−12 kcal/mol) compared with the
peptide alone (−6 kcal/mol). The peptide part of 5b was bound to a grove near amino acids
Lys56, Asn79, Glu181 and Lys185 of EGFR, which are away from the binding site of EGF.
The Pc part of conjugate 5b was anchored to the other face around Pro171 of EGFR (see
Figure S56 of the Supporting Information). These results suggest that the Pc-peptide
conjugates should bind to EGFR with even higher affinity than the peptides alone. A surface
plasmon resonance (SPR) binding assay36, 37 was performed to confirm binding of the
peptides and Pc conjugates 5b and 6a to EGFR (see Table S1 and Figure S58 of the
Supporting Information). EGFR was immobilized on the chip surface and the relative
binding of different ligands was analyzed. The binding of high affinity ligand EGF to EGFR
was clearly seen in SPR. Other ligands and Pc conjugates reported in this study showed
relatively lower affinity to EGFR. Conjugate 6a was found to have the highest affinity for
EGFR, followed by 5b. The peptides alone bound with lower affinities than the Pc
conjugates, and EGFR-L2 showed higher affinity for EGFR than EGFR-L1, in agreement
with the docking studies. The Pc-PEG 3b was also observed to bind to EGFR but with lower
affinity than the Pc-peptide conjugates.
3. Cell culture
Four cell lines with different EGFR expressions were used to investigate the cytotoxicity,
uptake and subcellular distribution of Pc-peptide conjugates 4b, 5a, 5b and 6a: human
squamous cell carcinoma HEp2,28, 29, 38, 39 human epidermoid carcinoma A431,41–43
cercopithecus aethiops kidney Vero (as negative control),44 and human colorectal
adenocarcinoma HT-29 cells.45–47 The model human HEp2 cells are often used in the
investigation of peptide-fluorophore conjugates, while the human A431 cells are a positive
control for high EGFR expression (~1–3 million EGFR per cell), and the African green
monkey Vero cells are a negative control (lowest expression of EGFR). The human
colorectal adenocarcinoma HT-29 cells over-express EGFR, although to a lower degree
(~9000 EGFR per cell) than the A431 cells.45–47
Cytotoxicity—The dark- and photo-cytotoxicity for Pc-PEG 3a and Pc-peptide conjugates
4b, 5a,b and 6a were evaluated in all cell lines at concentrations up to 125 µM, using the
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Cell Titer Blue Assay, and the results are summarized in Table 2 and shown in Figures S20
and S21 of the Supporting Information. None of the Pcs was found to be toxic in the dark,
with determined IC50 values for all Pcs above 125 µM, the highest concentration
investigated. Upon exposure to a low light dose (1 J/cm2), only Pc 5a bearing the EGFR-L1
peptide was found toxic to A431, HEp2 and Vero cells (IC50 = 16, 17 and 47 µM,
respectively). In human carcinoma HEp2 cells, Pc conjugate 5a was significantly more
phototoxic than 5b (IC50 ~ 100 µM), in agreement with our recent observations showing that
α-substituted Pcs tend to be more phototoxic than the corresponding β-substituted Pcs.29 On
the other hand, none of the Pcs were phototoxic to human HT-29 cells, suggesting that this
type of conjugate could potentially be used for imaging of colorectal tumors. Low toxicity is
an important feature of potential new imaging agents to be employed in conjunction with
CLE. The Pc-EGFR-L1 conjugate 5a was significantly more phototoxic than the
corresponding Pc-EGFR-L2 conjugate 6a, which might be a result of its higher uptake into
cells due to its cationic charge (vide infra). The presence of the PEG linker did not have an
effect on the observed cytotoxicity of the conjugates, although it increased their aqueous
solubility.
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Time-dependent uptake—The time-dependent cellular uptake for all Pcs was performed
at the non-toxic concentration of 10 µM in all cell lines, and the results are shown in Figure
2. There were marked differences in the cellular uptake of the Pc-EGFR-L1 conjugates
compared with the Pc-EGFR-L2 conjugates, which might be due to their different overall
charge, solubility and tendency for aggregation. While the highly hydrophobic and
uncharged Pc-EGFR-L2 conjugates 4b and 6a were poorly taken up by all cell lines, in
particular by A431 and HT-29 cells which over-express EGFR, the positively charged PcEGFR-L1 conjugates 5a and 5b accumulated within cells to a much higher extent. Cells
with higher EGFR expression showed higher uptake of the Pc conjugates, about 4-fold
increase in A431 vs Vero cells, and a 3- or 2-fold increase in HT-29 colorectal and HEp2
cancer cells, respectively. This result shows that Pc conjugates 5a and 5b can indeed target
cancer cells over-expressing EGFR, in particular CRC cells. It is interesting to compare the
very different Pc uptake into Vero cells, with low expression of EGFR; Pc conjugate 5b
accumulated the fastest, followed by 5a and precursor Pc-PEG 3a. The Pc-EGFR-L2
conjugates 4b and 6a were taken up by Vero cells to a much lower extent than the PcEGFR-L1 conjugates 5a,b, and 6a bearing a PEG linker accumulated ~ 2-fold higher than
4b. These results show that the Pc macrocycle has a natural tendency to accumulate within
cells, with or without over-expression of EGFR, and that the PEG-containing compounds
tend to be taken up to a higher extent. The conjugation of the Pc to a small cationic peptide
sequence (EGFR-L1) changes the uptake kinetics, as seen in Figure 2b, and as previously
observed.39 In EGFR over-expressing cells, Pc conjugates 5a and 5b clearly were taken up
the most of all Pcs investigated. For example, in A431 cells, conjugates 5a and 5b
accumulated ~15-fold more than Pc-PEG 3a and than the Pc-EGFR-L2 conjugates 4b and
6a (Figure 2a). Similarly in HT-29 and HEp2 cells, 5a and 5b were taken up to a significant
higher extent than Pcs 3a, 4b and 6a. These results indicate that the peptide sequence has a
marked effect on the cell targeting and uptake ability of the Pc conjugates. Autodock and
SPR investigations show that peptides EGFR-L1 and EGFR-L2, and Pc conjugates 4b, 5b
and 6a bind to EGFR (vide supra). Although Pc-EGFR-L2 conjugates can bind to EGFR
with high specificity and be retained at the cell surface rather than internalized, their low
uptake into Vero cells with low expression of EGFR suggests that their low solubility and
high tendency for aggregation are responsible for their observed low cellular uptake. Indeed,
the least soluble Pc 4b accumulated the least within cells compared with all Pcs investigated,
although this conjugate gave the lowest docking energy (−17 kcal/mol) of all molecules
investigated. On the other hand, the Pc-EGFR-L1 conjugates bearing an arginine residue and
overall +1 charge were readily taken up by all cells, as we have previously observed for
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porphyrin-peptide conjugates bearing 1 to 4 positively charged residues.48 Positively
charged molecules have been observed to have enhanced ability for crossing negatively
charged plasma membranes, in particular those containing arginine due to the unique ability
of the protonated guanidinium group to form bidentate hydrogen bonds.48–52
Of all Pc-peptide conjugates investigated, 5b accumulated the fastest within all cell lines,
followed by 5a, which was found in the highest amount within A431 and HT-29 cells, at
times > 8 h after Pc exposure. Because of its rapid and efficient uptake into cells and low
cytotoxicity, Pc conjugate 5b was chosen for further investigation in animal studies (vide
infra).
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Subcellular Localization—The preferential sites of intracellular localization of Pcpeptide conjugates 4b, 5a,b and 6a and Pc-PEG 3a were evaluated using fluorescence
microscopy, in the three human cell lines over-expressing EGFR, i.e. A431, HT-29 and
HEp2 cells. The results are summarized in Table 3 and shown in Figures 3 and 4 for
conjugate 5b and in the Supporting Information, Figures S1–S13. Co-localization
experiments were performed using the organelle-specific probes LysoTracker Green
(lysosomes), ER Tracker Blue/White (ER), MitoTracker Green (mitochondria) and BODIPY
Ceramide (Golgi). All conjugates localized in multiple sites within the cells. The Pc-EGFRL1 conjugate 5b was found in the lysosomes, mitochondria and Golgi of all cell lines; in
addition its regioisomer 5a was also observed in the ER, which might in part explain its
higher phototoxicity compared with 5b.53, 54 Pc-EGFR-L2 conjugates 4b and 6a were also
found in lysosomes, Golgi and mitochondria. Lysosomal localization might result from an
endocytic pathway of this type of molecules, as we have previously observed.28, 48
We also investigated potential fluorescence from the Pc conjugates on the plasma
membrane, in order to detect any non-internalized EGFR-bound conjugate. However, no
fluorescence was detected by microscopy, indicating that the Pc conjugates do not localize
on the plasma membrane. No co-localization was observed with fluorescent probe 1-(4trimethylammoniumphenyl)-6-phenyl-1,3,5-hexatriene p-toluenesulfonate (TMA-DPH) that
specifically labels the plasma membrane. This result indicates that the Pc-EGFR-L2
conjugates have poor EGFR targeting ability, probably because of their low solubility and
high tendency for aggregation. On the other hand, the Pc-EGFR-L1 conjugates 5a and 5b
efficiently target EGFR over-expressing cells and are internalized, to a level that is
dependent on the degree of EGFR expression.
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4. Mouse studies
Pc-peptide conjugate 5b was chosen for further evaluation in mouse studies, due to its low
cytotoxicity and rapid accumulation within cells in vitro. Following iv administration of 10
mg/kg of Pc 5b, nude mice showed the emergence of tumor-selective fluorescence
indicating that the conjugate was taken up into both A431 and HT-29 s.c. tumors.
Fluorescence signal which exceeded the background of adjacent skin regions became
apparent at 24 h in both tumor types (representative mice shown in Figure 5).
Microscopically, 5b deposition in the tumor tissue was not homogeneous but rather seemed
to occur in a multifocal pattern perhaps reflecting regions of greater vascularity (Figure 6);
however, sufficient Pc 5b accumulated within the entire tumor to result in a near-IR
fluorescence signal distinguishing tumor above adjacent normal tissue. Quantitatively, the
signal in the HT-29 tumors declined from 24 to 96 h and could not be readily differentiated
from adjacent regions without tumor at 96 h. Preliminary studies with the Kodak In Vivo FX
imager, demonstrated that in order to visualize a fluorescence signal, that signal needed to
be at least 1.2-fold greater than adjacent regions of the mouse. The fluorescence signal
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emission in the A431 tumor continued to increase to 96 h (Figure 7) suggesting continued
uptake of the Pc conjugate over a longer time period in cells over-expressing EGFR.
For purposes of comparison, the two tumor groups were not significantly different in tumor
size (A431= 133.3 ± 28.7 cm3 and HT-29 = 141.9± 21.4 cm3 at 96 h). Neither tumor
demonstrated auto-fluorescence at the 630/700 nm spectra window at time 0 when compared
with adjacent skin surfaces.
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In vivo, tumor-associated fluorescence excitable at 630 and emitted at 700 nm was
detectable at 24 h. Correspondence of these wavelengths to the Pc conjugate spectra
indicates uptake of the conjugate by the two subcutaneous human tumor xenografts. While
both HT-29 and A431 cells over-express EGFR, there is a vast difference in the degree of
receptor expression, with A431 ~ 200 times higher EGFR expression than HT-29.43–45 If the
Pc conjugate homed to the tumor tissue based solely on the presence of the EGFR ligand, we
would not have expected to observe the comparable levels of fluorescence from both tumors
at 24 h. Therefore, in addition to tumor attraction based on EGFR-peptide binding, our
results suggest significant tumor homing by the Pc macrocycle itself, in agreement with the
in vitro results (see Figure 2b) and previous observations.8 The extended fluorescence-time
within the A431 tumor over the HT-29 tumor suggests that with greater quantities of EGFR,
comes longer retention and/or greater capacity for selective uptake or re-uptake. At times
prior to 24 h, we found no or weak signal, suggesting a prolonged time period of plasma
circulation with gradual tumor accumulation. A similar pattern of tumor uptake was recently
described in a xenograph breast cancer model imaged following administration of a chiral
porphyrazine,55 which showed increasing signal over background up to 48 h post
administration. On the other hand, chlorin e6-HSA nanoparticles were recently used for
PDT of HT-29 tumor xenograph,56 and shown to have higher tumor-targeting ability and
accumulation than free chlorin e6 as a result of their prolonged blood circulation. Two other
chlorin derivatives, HPPH-3Gd(II)ADTPA57 and TCPCSO3H58 were recently shown to
accumulate within tumor-bearing mice, reaching maximum accumulation levels at 24 h
post-administration.
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We detected no signal in adjacent non-tumor regions indicating a high degree of tumor
selectivity; however, we noted that normal gastrointestinal contents in the mice also
fluoresced at the near-IR spectra window required for this Pc-conjugate. This background
fluorescence is difficult to remove in mice since prolonged fasting is not feasible. For
imaging of colon or urogenital malignancies, it would likely be necessary to remove fecal
material prior to tumor detection.
In order to evaluate the in vivo stability of conjugate 5b, the HT-29 tumors were harvested
at 24 and 96 h following iv injection and extracted using acetone/methanol mixture. The
UV-vis spectra of both the 24 and 96 h tumor extracts in methanol showed the characteristic
Q band absorption of the Pc (Supporting Information, Figure S19), indicating that the Pc
macrocycle has high stability in vivo, allowing for prolonged and selective accumulation
within tumor tissue. MALDI-TOF MS indicated that at 24 h, intact conjugate 5b was still
present in the tumor extract, while at 96 h the major Pc species detected was Pc-PEG-LARL
(Supporting Information, Figures S53 and S54). This result suggests that the EGFR-L1
peptide in Pc 5b is slowly degraded within tumor tissue by proteolytic enzymes, mainly
losing the two terminal amino acids 96 h after iv injection. This result is in agreement with
our previous observations that this type of peptide conjugate can undergo metabolic
degradation within tumor cells, with half life ~ 24 h.59
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Conclusions
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Four Pc-peptide conjugates (4b, 5a, 5b and 6a) were designed and synthesized to target
EGFR, and investigated as potential florescence imaging agents for cancers over-expressing
EGFR, such as CRC. Two peptide ligands for EGFR containing 6 (LARLLT) and 13
(GYHWYGYTPQNVI) amino acid residues, were conjugated to the Pc via a short 5-atom,
or a 13-atom PEG linker. The PEG group enhances the solubility of the Pc-peptide
conjugates and tends to increase their cellular uptake. Using Autodock both peptide ligands
were found to bind to EGFR, giving low energy (−6 kcal/mol) docking structures, while
conjugation to the Pc gave even lower docking energies (−8 to −17 kcal/mol) due to
additional interactions of the Pc macrocycle with hydrophobic residues on EGFR. SPR
studies confirmed the binding of Pc-peptide conjugates to EGFR.

$watermark-text

The short EGFR-L1 peptide conjugates 5a and 5b are positively charged and were
efficiently internalized by all cell lines (A431, HT-29, HEp2 and Vero cells), localizing
preferentially in lysosomes, Golgi and mitochondria. On the other hand, the 13-residue
EGFR-L2 peptide produced highly hydrophobic Pc conjugates 4b and 6a that, mainly as a
result of their poor water-solubility and high tendency for aggregation, poorly targeted
EGFR at the plasma membranes and were poorly internalized. The amount of Pc-EGFR-L1
conjugates, 5a and 5b, taken up by cells was dependent on their degree of EGFR expression.
While 5a and 5b, as well as Pc-PEG 3a also accumulated within the low EGFR expressing
Vero cells, increased uptake was observed with increasing EGFR expression in the human
cell lines (A431 > Ht-29 > HEp2). The observed uptake into low EGFR expressing cells
indicates that the Pc macrocycle has a natural tendency to target and accumulate within
cancer cells.
All conjugates were found to be non-toxic (IC50 > 100 µM) to both low- and overexpressing EGFR cells, with exception of conjugate 5a that showed moderate phototoxicity
toward A341, HEp2 and Vero cells (IC50 = 16, 17 and 47 µM, respectively). None of the
conjugates were toxic towards human colorectal HT-29 cells (IC50 > 100 µM). This result,
in addition to the observed near-IR fluorescence emissions of all Pc conjugates at ca. 682
nm with quantum yields in the range 0.10–0.13, and enhanced uptake of 5a and 5b by
cancer cells, makes these Pc-EGFR-L1 conjugates highly promising fluorescent contrast
agents for CRC, and potentially other EGFR over-expressing cancers, in particular the least
phototoxic (IC50 > 100 µM at 1 J/cm2) β-substituted Pc-peptide conjugate 5b.
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Conjugate 5b was further investigated in nude mice bearing A431 and HT-29 human tumor
xenografts. Twenty four hours after iv administration of 5b, a clearly near-IR fluorescence
signal (exc 630 nm/ em 700 nm) was seen over background adjacent tissues, in both tumor
types. While the fluorescence signal decreased in HT-29 tumors after 24 h, it continued to
increase in the A431 tumors up to 96 h, the longest time investigated. The MS analysis of
tumor extracts 96 h after iv injection of Pc-peptide 5b indicated partial degradation of the
conjugate, by proteolytic enzymes, mainly leading to the cleavage of the last two amino
acids of EGFR-L1.
Our studies show that Pc-peptide conjugates can be used for near-IR fluorescence imaging
of cancers over-expressing EGFR, such as CRC. Due to the hydrophobic nature of the Pc
macrocycle, a low molecular PEG linker and a polar or charged peptide ligand are required
for adequate aqueous solubility and receptor targeting ability. In addition, a β-substituted Pc
macrocycle appears to be the most suitable for imaging applications due to its lower
phototoxicity compared with the corresponding α-substituted macrocycle.
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Figure 1.

Low energy docked structure of (a) EGFR-L1 and (b) EGFR-L2 peptides with EGFR
receptor. EGFR is shown in surface and the peptide is shown as dark sticks. The EGF
binding pocket is shown.

$watermark-text
J Med Chem. Author manuscript; available in PMC 2013 April 26.

Ongarora et al.

Page 22

$watermark-text
$watermark-text
Figure 2.

Time-dependent uptake of Pcs 3a (blue), 4b (orange), 5a (purple), 5b (turquoise) and 6a
(red) at 10 µM by (a) A431, (b) Vero, (c) HEp2 and (d) HT-29 cells.
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Figure 3.

Subcellular fluorescence of Pc 5b in A431 cells at 10 µM for 6 h. (a) Phase contrast, (b)
Overlay of 5b fluorescence and phase contrast, (c) ER Tracker Blue/White fluorescence, (e)
MitoTracker green fluorescence, (g) BODIPY Ceramide, (i) LysoSensor green fluorescence,
and (d, f, h, j) overlays of organelle tracers with 5b fluorescence. Scale bar: 10 µm.
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Figure 4.

Subcellular fluorescence of Pc 5b in HT-29 cells at 10 µM for 6 h. (a) Phase contrast, (b)
Overlay of 5b fluorescence and phase contrast, (c) ER Tracker Blue/White fluorescence, (e)
MitoTracker green fluorescence, (g) BODIPY Ceramide, (i) LysoSensor green fluorescence,
and (d, f, h, j) overlays of organelle tracers with 5b fluorescence. Scale bar: 10 µm.
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Figure 5.

Fluorescent images (exc 630 nm/em 700 nm) of nude mice bearing s.c tumor implants of
A431 (top) or HT-29 (bottom) cancer cells at various times following iv administration of
Pc 5b. The tumor positions are circled and the left panel of HT-29 mouse shows the eGFP
tumor fluorescence (exc 490 nm/em 535 nm).
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Figure 6.

Deposition of Pc 5b in the HT-29 tumor xenograph, 24 h following iv injection. Images
show (a) eGFP indicating HT-29 tumor regions, (b) Pc 5b fluorescence, and (c) overlap of
tumor and Pc deposition.
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Figure 7.
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Emission signal of Pc 5b at 700 nm in the s.c. human tumor xenographs, over the adjacent
(background) skin regions, expressed as a percent. To visually distinguish tumors by
fluorescence, the tumor needs to be at least 120% of adjacent regions.
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Scheme 1a

aConditions: (a) 1,4-dioxane-2, 6-dione, DMF, r.t., (87–92%); (b) tert-butyl-12-
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amino-4,7,10-trioxadodecanoate, DIEA, HOBt, EDCI, DMF, 72 h, r.t., (77–82%); (c) TFA,
dichloromethane, 4 h, (88.3–89.3 %); (d) DIEA, HOBt, TBTU, EGFR-L1 or EGFR-L2,
DMF, 24 h, then TFA/H2O/phenol/TIS 88/5/5/2 (20–80%).
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Spectroscopic Properties of Pcs in DMF.
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Table 2

Dark and photo cytotoxicity for Pc conjugates using the Cell Titer Blue assay.
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Compound

A431 cells
IC50 (µM)
Light/dark

Vero cells
IC50 (µM)
Light/dark

HEp2 cells
IC50 (µM)
Light/dark

HT-29 cells
IC50 (µM)
Light/dark

3a

>100/>125

>100/>125

>100/>125

>100/>125

4b

>100/>125

>100/>125

>100/>125

>100/>125

5a

15.8/>125

47.0/>125

17.0/>125

>100/>125

5b

>100/>125

>100/>125

>100/>125

>100/>125

6a

>100/>125

>100/>125

>100/>125

>100/>125
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Table 3

Main subcellular sites of localization for Pc conjugates in human cells.
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Compound

A431 cells

HEp2 cells

HT-29 cells

3a

Lyso, Golgi, Mito

Lyso, Golgi

Lyso

4b

Lyso, Golgi, Mito

Lyso, Golgi, Mito

Lyso, Golgi, Mito

5a

Lyso, Golgi, Mito, ER

Lyso, Golgi, Mito, ER

Lyso, Mito

5b

Lyso, Golgi, Mito

Lyso, Golgi, Mito

Lyso, Golgi, Mito

6a

Lyso, Golgi, Mito

Lyso, Golgi, Mito

Lyso, ER
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